Literature DB >> 19929752

Analytical performance of the serum free light chain assay.

Pierre-Yves Briand1, Olivier Decaux, Hélène Caillon, Bernard Grosbois, André Le Treut, Lucienne Guenet.   

Abstract

BACKGROUND: The Freelite system for nephelometric or turbidimetric measurement of serum free light chains (FLCs) has been available since 2001. It has been valuable for the management of patients with oligosecretory myeloma, light chain myeloma and AL amyloidosis. However, there are several limitations of the method. The goal of this study was to evaluate the analytical performance of the FLC assay.
METHODS: Titrated controls and clinical serum specimens were used to determine precision and post-dilution recovery.
RESULTS: As reported elsewhere, we found that the assay had several limitations, including poor post-dilution linearity and overestimation by nephelometry.
CONCLUSIONS: These data demonstrate that the results of the FLC assay must be interpreted jointly by the clinician and the biologist, taking into account the individual patient's clinical and biological characteristics.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19929752     DOI: 10.1515/CCLM.2010.012

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  6 in total

1.  Defining the impact of individual sample variability on routine immunoassay of serum free light chains (sFLC) in multiple myeloma.

Authors:  S H K Murng; L Follows; P Whitfield; J A Snowden; K Swallow; K Green; R Sargur; W Egner
Journal:  Clin Exp Immunol       Date:  2013-02       Impact factor: 4.330

2.  The analytical performance evaluation of Freelite™ Human Kappa Free and Human Lambda Free on the SPAPLUS™ immunoturbidimetric analyzer.

Authors:  Kyong-Ho Cha; Yang Bo Sim; Hyojin Chae; Hae-il Park; Myungshin Kim; Yonggoo Kim
Journal:  J Clin Lab Anal       Date:  2014-01-29       Impact factor: 2.352

3.  Polyclonal free light chains: a biomarker of inflammatory disease or treatment target?

Authors:  Judith A Brebner; Robert A Stockley
Journal:  F1000 Med Rep       Date:  2013-02-01

4.  Relationship between circulating syndecan-1 levels (CD138s) and serum free light chains in monoclonal gammopathies.

Authors:  Giovanni Cigliana; Eleonora Torti; Francesca Gulli; Elena De Santis; Maria Teresa Dell'Abate; Luigi Colacicco; Francesco Pisani; Laura Conti; Umberto Basile
Journal:  J Exp Clin Cancer Res       Date:  2015-04-23

5.  Effect of specimen type on free immunoglobulin light chains analysis on the Roche Diagnostics cobas 8000 analyzer.

Authors:  Louis S Nelson; Bryan Steussy; Cory S Morris; Matthew D Krasowski
Journal:  Springerplus       Date:  2015-12-08

6.  Clinical comparisons of two free light chain assays to immunofixation electrophoresis for detecting monoclonal gammopathy.

Authors:  Han-Sung Kim; Hyun Soo Kim; Kyu-Sung Shin; Wonkeun Song; Hyo Jung Kim; Hyeong Su Kim; Min-Jeong Park
Journal:  Biomed Res Int       Date:  2014-05-27       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.